NAS:AGLE (USA)

Aeglea BioTherapeutics Inc

$ 6.33 0.15 (2.43%)
Volume: 231,185 Avg Vol (1m): 181,358
Market Cap $: 183.19 Mil Enterprise Value $: 59.48 Mil
P/E (TTM): 0.00 P/B: 1.66
Earnings Power Value 0.63
Net Current Asset Value 3.95
Tangible Book 4.01
Projected FCF 0
Median P/S Value 2.06
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
68.92% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AGLE: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Interest Coverage No Debt
Interest Coverage ranked higher than
61.80% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
AGLE: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.43
DISTRESS
GREY
SAFE
Beneish M-Score -4.18
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 7.74%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1411.39
Operating Margin ranked lower than
68.56% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
AGLE: -1411.39
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1411.39, Med: -502.53, Max: -185.95
Current: -1411.39
-1411.39
-185.95
Net Margin % -1373.35
Net Margin ranked lower than
68.56% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
AGLE: -1373.35
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1373.35, Med: -496.06, Max: -185.62
Current: -1373.35
-1373.35
-185.62
ROE % -73.19
ROE ranked lower than
56.62% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AGLE: -73.19
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -106.47, Med: -75.32, Max: -48.08
Current: -73.19
-106.47
-48.08
ROA % -65.59
ROA ranked lower than
61.99% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AGLE: -65.59
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -274.93, Med: -54.32, Max: -41.05
Current: -65.59
-274.93
-41.05
ROC (Joel Greenblatt) % -5574.46
ROC (Joel Greenblatt) ranked lower than
75.58% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AGLE: -5574.46
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -10992.59, Med: -3928.46, Max: -704.76
Current: -5574.46
-10992.59
-704.76
3-Year Total Revenue Growth Rate -13.90
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
AGLE: -29.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -29.4
Current: -29.4
0
-29.4
3-Year Total EBITDA Growth Rate -59.10
3-Year EBITDA Growth Rate ranked lower than
66.96% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AGLE: -30.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -30.2, Max: -11.6
Current: -30.2
0
-11.6
3-Year EPS w/o NRI Growth Rate -8.00
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
AGLE: -8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -8
Current: -8
0
-8

» AGLE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AGLE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XTER:PA8 NAS:PTI ROCO:3176 SSE:3055 XPAR:POXEL ROCO:6547 XBRU:THR XKRX:217730 XPAR:SIGHT NAS:IMDZ NAS:XBIT XCNQ:MYM ROCO:4743 OSL:SOLON NAS:XOMA NAS:NSTG NAS:CNAT NAS:PETX XKRX:115180 XTAE:NTEC
Traded in other countries
Address 901 S. MoPac Expressway, Suite 250, Barton Oaks Plaza One, Austin, TX, USA, 78746
Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer.

Ratios

Current vs industry vs history
PB Ratio 1.66
PB Ratio ranked higher than
54.89% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AGLE: 1.66
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.76, Med: 1.71, Max: 4.07
Current: 1.66
0.76
4.07
PS Ratio 55.19
PS Ratio ranked lower than
65.15% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
AGLE: 55.19
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 8.15, Med: 17.88, Max: 76.26
Current: 55.19
8.15
76.26
EV-to-EBIT -1.11
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AGLE: -1.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -4.7, Med: -1.45, Max: 1.4
Current: -1.11
-4.7
1.4
EV-to-EBITDA -1.12
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AGLE: -1.12
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -4.7, Med: -1.5, Max: 1.4
Current: -1.12
-4.7
1.4
EV-to-Revenue 15.26
EV-to-Revenue ranked lower than
62.39% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
AGLE: 15.26
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -4.9, Med: 7.8, Max: 55
Current: 15.26
-4.9
55
Current Ratio 10.74
Current Ratio ranked higher than
71.79% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AGLE: 10.74
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.58, Med: 13.88, Max: 37.12
Current: 10.74
2.58
37.12
Quick Ratio 10.74
Quick Ratio ranked higher than
72.35% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AGLE: 10.74
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.58, Med: 13.88, Max: 37.12
Current: 10.74
2.58
37.12

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -28.00
3-Year Share Buyback Rate ranked lower than
77.71% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AGLE: -28
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -34.7, Med: -28, Max: 0
Current: -28
-34.7
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.58
Price-to-Tangible-Book ranked higher than
61.86% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
AGLE: 1.58
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.88, Med: 1.77, Max: 3.8
Current: 1.58
0.88
3.8
Price-to-Median-PS-Value 3.08
Price-to-Median-PS-Value ranked lower than
78.32% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
AGLE: 3.08
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.61, Med: 1.01, Max: 3.93
Current: 3.08
0.61
3.93
Earnings Yield (Joel Greenblatt) % -92.35
Earnings Yield (Greenblatt) ranked lower than
68.09% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AGLE: -92.35
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -4619.9, Med: -39.8, Max: 9899.8
Current: -92.35
-4619.9
9899.8

More Statistics

Revenue (TTM) (Mil) $ 3.89
EPS (TTM) $ -2.23
Beta 0.98
Volatility % 51.49
52-Week Range $ 5.99 - 11.37
Shares Outstanding (Mil) 28.85

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N